“Rise of Targeted Therapies and Immunotherapies”
A key trend shaping the gastric cancer drug market is the rise of targeted therapies and immunotherapies, driven by advancements in molecular biology and precision medicine. These treatments are designed to target specific genetic markers or proteins associated with gastric cancer, improving efficacy and reducing side effects compared to traditional therapies. For instance, the approval of trastuzumab deruxtecan for HER2-positive gastric cancer patients has opened new avenues for treating cases with limited therapeutic options. In addition, checkpoint inhibitors such as pembrolizumab are being explored for their potential in treating advanced or metastatic gastric cancers. This trend aligns with the increasing emphasis on personalized medicine, which tailors treatments based on individual patient profiles. The growing pipeline of such therapies and the integration of companion diagnostics to identify suitable candidates further highlight the shift towards innovative and patient-centric solutions, significantly influencing the market's growth trajectory.
